An interventional study of Vitamin D supplement in Overweight and Hypovitaminosis D, sponsored by Tirang R. Neyestani, Ph.D.. Completed at 1 site in Iran, Islamic Republic of. Open to female participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-17.
Sponsored by Tirang R. Neyestani, Ph.D. · Not applicable, Interventional, and Treatment
Among 19 studies in Overweight with a site in Iran, Islamic Republic of — 1 open to participants now, 1 under way, none of them phase 3. Overweight · Iran, Islamic Republic of.
Among the 19 studies in Overweight with a site in Iran, Islamic Republic of, this one is the 18th largest by enrollment, is the only one that started in 2021, is one of 18 with no phase, and was the 18th registered.
3,599 studies on the registry are indexed under Overweight; 852 are open to participants now.
Browse Overweight studies →1 of the 19 studies in Overweight with a site in Iran, Islamic Republic of is open now. Recruiting first, the newest first:
University of Tehran · Sites in Iran, Islamic Republic of
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Iran, Islamic Republic of have not opened yet or have stopped. Only those recruiting at a site in Iran, Islamic Republic of →
Of the 529 Overweight studies recruiting now, 158 (30%) set no upper age limit and 343 (65%) stop at 75 or younger; 62 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 78 across 3,120 interventional studies indexed under Overweight.
Median enrollment 81 across the 19 interventional studies. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 7 most frequent:
Tirang R. Neyestani, Ph.D. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Tirang R. Neyestani, Ph.D. has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Overweight with a site in Iran, Islamic Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
46 eligible overweight women with hypovitaminosis D are assigned to either vitamin D or control group using block randomization method. Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) containing 50000 IU cholecalciferol or placebo are administered weekly for 12 weeks. Participants in both groups are structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study.
For the randomized controlled clinical trial (RCT), the first fifty eligible women were assigned to either the vitamin D or placebo group using the block randomization method. Each Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) contained 50000 IU cholecalciferol and was administered weekly for 12 weeks according to guidelines for treating vitamin D deficiency. Placebo pearls (Zahravi Pharma Co, Tabriz, Iran) had the identical appearance, taste, and smell as the vitamin D pearls and could only be identified by the package code. The placebo pearls were administered similarly. To keep the study double-blinded, an assistant who was not involved in assessments managed the randomization and supplement assignment procedure. Participants were structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study. They were also asked to inform the researcher before taking any new medications. All participants were provided with a moderately reduced diet (a reduction of 300 kcal per day) based on their basal weight. The nutrigenetic study investigated 75 eligible women (including the vitamin D group and the last fifty women who entered the study). The nutrigenetic study protocol was the same as that mentioned above for the vitamin D group in the RCT. Compliance was ensured by weekly text messages and voice calls to remind the users of the supplement on the given day. In addition, the supplement and placebo pearls were presented in two visits; once at the baseline visit and then after six weeks. Pearls packs were collected from each subject (at week 6 and week 12) to check if all the pearls were consumed as recommended.
During the first and last visits, anthropometric and laboratory assessments were performed for all subjects. The primary outcomes are improving anthropometric, inflammatory, and metabolic markers of overweight women with hypovitaminosis D.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vitamin D3 supplement every week
Dietary Supplement: Vitamin D supplement
Placebo every week
Dietary Supplement: Vitamin D supplement
The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
Serum 25(OH)D
Fasting serum 25-hydroxyvitamin D level
Time frame: 12 weeks
Weight
Subject's weight wearing light clothing
Time frame: 12 weeks
Waist circumference
the measurement at the midpoint between the lowest rib and the iliac crest
Time frame: 12 weeks
Fat mass
Total body fat mass measured by Bioelectrical Impedance analysis method
Time frame: 12 weeks
Serum Fasting Glucose
Fasting serum glucose level
Time frame: 12 weeks
Serum total cholesterol
Fasting serum total cholesterol level
Time frame: 12 weeks
Serum triglyceride
Fasting serum triglyceride level Fasting serum triglyceride leve
Time frame: 12 weeks
Serum hsCRP
Fasting serum high sensitivity c-reactive protein level
Time frame: 12 weeks
Serum IL-6
Fasting serum Interleukin-6 level
Time frame: 12 weeks
Serum TNF-a
Fasting serum tumor necrosis factor alpha level
Time frame: 12 weeks
Serum PTH
Fasting serum parathyroid hormone level
Time frame: 12 weeks
Ran from Sep 2021 to primary completion in Dec 2021, 3 months.
Of 1,300 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 3 months is below that.
Counting every sponsor, half of 1,411 studies reached it within 17 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vitamin D
Tirang R. Neyestani, Ph.D.